Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* body weight ≥40 kg and ≤125 kg~* previously documented CHC genotype 1 infection;~* must have a liver biopsy with histology consistent with CHC and no other etiology~* if cirrhosis present, must have an ultrasound within 6 months of the screening visit (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC)~* agree to use acceptable methods of contraception with partner~* previously untreated with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV or failing prior treatment with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV~Exclusion criteria:~* co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus (Hepatitis B surface antigen \[HBsAg\] positive).~* required discontinuation of previous interferon or ribavirin regimen for an adverse event (possibly or probably related)~* treatment with ribavirin within 90 days and any interferon-alpha, based on the amendment, should be within 1 month prior to screening~* treatment with any investigational drug within 30 days of the screening visit in this trial~* evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy~* diabetic and/or hypertensive with clinically significant ocular examination findings~* clinical diagnosis of substance abuse of specified drugs within specified timeframes~* any known pre-existing medical condition that could interfere with the participant's participation in and completion of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RGT BOC + PR (Type: EXPERIMENTAL): Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
- PBO + PR (Control) (Type: PLACEBO_COMPARATOR): Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
- Crossover Arm (Type: EXPERIMENTAL): Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.

Based on this trial design, predict the completion outcome and termination type (if applicable).